METHODS
 Design This study was a randomized, double-blind, placebo controlled, parallel study. o Secondary measures of efficacy involved changes in several other depression rating scales including the Beck Depression Inventory (BDI), the Montgomery-Asberg Depression Rating Scale (MADRS), the Clinical Global Impression Scale (CGI), and the Patient's Global Improvement Scale (PGI).  # enrolled per group: 42 subjects were randomized to 2 study arms. 20 subjects received citalopram + omega-3 and 22 received citalopram + placebo.  Drug Regimen: At the end a 1 week run-in phase, subjects still with a HAM-D score greater than 17 were block randomized by sex to receive citalopram 20mg daily. Half of the subjects also received omega-3 fatty acids and the other half received placebo. Subjects were instructed to take citalopram in the morning and two omega-3 or placebo capsules twice daily with meals. All subjects remained on citalopram 20mg daily until week 4 of the study, after which the dose could be increased to 40mg/day if HAM-D scores had decreased less than 25% and adverse effects were not a concern.  Power: 80% power to detect a decrease in HAM-D scores with an effect size ranging between 0.8-1 at α=0.05.
 Data Handling: Intent-to-treat analysis

RESULTS:
 Number of patients completing study: 33 total patients completed the study. 18 patients in treatment group and 15 in placebo group.  Primary outcome measure: there was significantly greater improvement over time in HAM-D scores among subjects in the omega-3 FA group compared to placebo (p=0.008). Significant differences were noted between the treatment groups at study week 4, week 6, and week 8 (p=0.005, p=0.008, p=0.004)  Secondary outcome measures: There was also statistically significant improvement in remission status in the omega-3 group compared to placebo (p=0.018). There were "trends" for group vs. time interaction for BDI scores and MADRS scores (p=0.018).  Authors Conclusions: Omega-3 fatty acid supplementation of citalopram produced a significantly greater reduction in HAM-D scores compared to citalopram treatment alone. There was no evidence of acceleration of antidepressant response with the addition of omega-3 fatty acid.
STRENGTHS
 Randomized, double-blind, placebo controlled, parallel study.  Good rationale for conducting study  No conflicts of interest  Appropriate inclusion/exclusion criteria WEAKNESSES  Small number of subjects  Large dropout rate (especially in placebo group)  Heterogeneity of subjects at baseline  Possible inappropriate dose and duration of therapy of omega-3 fatty acid  Recruitment of subjects by advertisement/physician referral  Did not determine if blinding was successful  Possible non-adherence to treatment regimens CONCLUSIONS  Based on this study alone, it should not be recommended to add omega-3 fatty acids to citalopram for the treatment of depression. Even though the results of this study showed statistical significance when omega-3 fatty acids were added to citalopram, key limitations prevent the usefulness of this study's results in clinical practice. These key limitations include small sample size, large dropout rate, and a large variability of subjects at baseline. Omega-3 fatty acids are inexpensive, have very few adverse reactions, and may be useful in patients with concurrent cardiovascular disease. If omega-3 fatty acids were tested in a larger study in patients with similar characteristics, omega-3 fatty acids may be a safe and effective treatment option in patients not achieving remission of depression with antidepressants.
